This morning, Biotalys provided an update on the regulatory approval process of the pilot product EVOCA™, concerning the deadline of the regulatory decision. Though the U.S. EPA has progressed on the regulatory pathway, the regulatory decision will be taken in Q4, instead of September (Q3).This is not a significant delay, especially because the company did not receive any additional questions or request for data.This update does not impact our investment case and we see no reason to change our p ....
